• PDF / 169,600 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 40 Downloads / 115 Views

DOWNLOAD

REPORT

---

1 S

Severe depression: case report A 63-year-old man developed severe depression during therapy with brivaracetam and levetiracetam for post-stroke focal onsets seizures [routes not stated]. The man, who had post-stroke focal onset seizures, was receiving levetiracetam 1g in the morning and 750mg at night daily. He had also been receiving various other medications. Two months after the initiation of levetiracetam, he became socially withdrawn. Hence, the man started receiving brivaracetam 25mg twice daily in incremental dosage, while levetiracetam dose was reduced to 250mg weekly. No previous psychiatric history was reported. Three weeks after the initiation of brivaracetam, he exhibited suicidal intent with physical aggression towards his relatives and carers. Hence, levetiracetam was stopped, along with the gradual increase of brivaracetam dose to 50mg twice daily. Afterwards, he had no seizures during several weeks of admission. However, he remained socially withdrawn, had a low mood and refused oral intake. Therefore, he was diagnosed with severe depression and was treated with sertraline. Subsequently, his symptoms improved, and brivaracetam was stopped. After discontinuation of brivaracetam, further improvement in his symptoms was noted. Eventually, he was discharged to the care of his family. Tiet MY, et al. Brivaracetam and levetiracetam dose adjustments leading to behavioural adverse effects. Postgraduate Medical Journal 93: 566, No. 1103, Sep 2017. Available 803449506 from: URL: http://doi.org/10.1136/postgradmedj-2017-134814

0114-9954/20/1788-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 25 Jan 2020 No. 1788